ResMed Inc. vs Workday Inc — how do they compare? ResMed Inc. trades at $224.27 (market cap $32.61B), while Workday Inc trades at $173.45 (market cap $44.77B). The key difference: Workday Inc is the larger of the two by market cap, and ResMed Inc. pays a 1.17% dividend while Workday Inc pays none. Which is the better fit depends on your goals.
| RMD | WDAY | |
|---|---|---|
Market Cap | $32.61B | $44.77B |
Sector | Health | Technology |
52-Week High | $293.73 | $247.69 |
52-Week Low | $182.82 | $112.55 |
Enterprise Value | $31.97B | $44.22B |
Dividend Yield | 1.17% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Workday (WDAY) trades at $184.19, up 2.53% with strong technical momentum and consecutive earnings beats. The stock shows bullish moving average signals despite overbought RSI readings. Revenue growth accelerated to $8.45 billion in 2025 with improving net margins of 6.22%, while analyst consensus remains positive with 55.6% buy ratings. Recent partnerships and AI product launches demonstrate continued innovation in enterprise software.
Outlook remains constructive given consistent earnings outperformance and AI-driven growth initiatives, though elevated valuation multiples and institutional selling present near-term headwinds. Key risks include competitive pressures and execution challenges in enterprise software market transitions.
Trailing returns across standard periods
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →